Navigation Links
International Collaboration: FDA and European Medicines Agency Agree to Accept a Single Orphan Drug Designation Annual Report
Date:2/26/2010

Voluntary move can save time, simplify development process

WHITE OAK, Md., Feb. 26 /PRNewswire-USNewswire/ -- In recognition of World Rare Disease Day, the U.S. Food and Drug Administration and the European Medicines Agency (EMA) today announced a more streamlined process to help regulators better identify and share information throughout the development process of orphan drug and biologic products, which are developed specifically to treat rare medical conditions. Both agencies have agreed to accept the submission of a single annual report from sponsors of orphan drug and biologic products designated by both the United States and the European Union.

(Logo:  http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO )

Currently, if an orphan product was granted designation on the exact same day in both the United States and European Union, sponsors must submit separate reports to their respective regulatory agency. The use of one annual report will also benefit sponsors by eliminating the duplication of efforts and by simplifying the process that meets the annual reporting requirements of both the United States and the European Union for orphan designated products.

"This process provides benefits for both agencies," said Timothy Cote, M.D., M.P.H., director of FDA's Office of Orphan Products Development. "Additionally, it reduces the duplication involved for sponsors in reporting to two separate regulatory agencies."

The single annual report, much like separate agency reports, will provide information to both agencies on the development of orphan medical products, including a review and status of ongoing clinical studies, a description of the investigation plan for the coming year and anticipated or current problems in the process that may impact their designation as an orphan product. The single annual report submission to both regulatory agencies is voluntary and will apply only to sponsors who have obtained an orphan designation status for their product from both the FDA and EMA.

The optional new process for submission will not introduce any additional regulatory requirements. Each regulatory body will conduct their own review and assessment of the annual report to assure the information meets all the legal and scientific requirements of each agency. The FDA and EMA will exchange the annual reports electronically through a secure portal. Starting Feb. 28, 2010 – World Rare Disease Day – sponsors may send the single Orphan Drug Designation Annual Report tomailto: both agencies. If they choose to do so, a sponsor may submit the report on their normal annual reporting date.

"We are very pleased with this collaboration on regulatory requirements and about sharing data that will help us understand the viability of the products," said Jordi Llinares, M.D., M.Sc., head of Orphan Medicines at the EMA.

Rare diseases are often chronic, progressive, degenerative, and often life-threatening. A disease or disorder is defined as rare in Europe when it affects less than 1 in 2,000 people (<250,000 people presently).  A disease or disorder is defined as rare in the United States if it affects fewer than 200,000 Americans at any given time. It is estimated that there are 6,000 to 8,000 rare diseases in the world today.

"This new step in our collaboration provides each of our agencies with information in real-time on any challenges arising during the development of products for rare diseases and will help identifying and acting on bottlenecks," added Kerstin Westermark, chair of the EMA's Committee for Orphan Medicinal Products.

For more information

Developing Products for Rare Diseases & Conditions

http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/default.htm

FDA International Programs – Europe

http://www.fda.gov/InternationalPrograms/FDABeyondOurBordersForeignOffices/EuropeanUnion/default.htm

World Rare Disease Day 2010

http://www.rarediseaseday.org/

U.S. inquiries: Jeff.Fritsch@fda.hhs.gov

EMA inquiries: orphandrugs@ema.europa.eu

U.S. Media Inquiries: Rita Chappelle, 301-796-4672, rita.chappelle@fda.hhs.gov

Trade Press Inquiries: Crystal Rice, 301-796-3111, crystal.rice@fda.hhs.gov

U.S. Consumer Inquiries:  1-888-INFO-FDA

EU Media Inquiries: Martin Havey Allchurch or Monika Benstetter, 011-44-(0)20-7418-8427, press@ema.europa.eu

SOURCE U.S. Food and Drug Administration

Back to top

RELATED LINKS
http://www.fda.gov

'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved


Related medicine news :

1. International study strengthens case for daily calcium pill
2. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
3. Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
4. LCA Hails International Investigators Studying Lung Cancer
5. Arrow International Urges Shareholders To Vote for Approval of the $45.50 Teleflex Inc. Merger and for the Current Board of Directors
6. PRA International Adds Dr. Susan Stansfield as Executive Vice President
7. Medical Services International Maintains Pace in Second Quarter
8. Clarity Imaging International, Inc. Rolls Out Mobile DEXA Program
9. International Gateway Insurance Brokers Partners With MEDILINQ
10. Tulane University to receive $14M for international HIV/AIDS program
11. International Database Seeks to Boost Treatment of Altitude Sickness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... Vighter established its NAEMT ... by providing Prehospital Trauma Life Support (PHTLS) course scholarships to four medics assigned ... education developed in cooperation with the American College of Surgeons to promote critical ...
(Date:3/24/2017)... ... March 24, 2017 , ... The Radiology Business Management Association (RBMA) ... annual awards, now in their 12th year, are among the most prestigious in radiology ... 2016, the awards were retooled to recognize achievements in both large budget (over $5,000) ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... and related services to families and business owners across eastern Michigan, is connecting ... regional families struggling with financial difficulties. , The Oxford/Orion FISH Food Pantry works ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... that they are now offering treatments for sleep apnea and TMJ at their ... Sleep apnea , specifically the obstructive type, is increasingly being treated at ...
(Date:3/24/2017)... ... March 24, 2017 , ... Gastro Health (“GH”) ... prep patients for colonoscopy at the HyGIeaCare® Center that is to be located ... , The HyGIeaCare® Prep, cleared by the U.S. Food and Drug ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... 24, 2017 The Board of Directors of ... Report 2016 including the complete 2016 Annual Accounts with notes. ... Nordic Nanovector,s website in the section Investor Relations/Reports and presentations/Annual ... ... Kvåle, Chief Financial Officer Cell: +47-91-51-95-76 Email: ir@nordicnanovector.com ...
(Date:3/23/2017)... Research and Markets has announced the addition ... Replacement Procedure By Technique, Repair Procedure By Technique, By Region, By ... ... forecasted to grow at a CAGR of 13.35% during 2016-2021 ... rising aging population, growth in population with heart disease and rising ...
(Date:3/23/2017)... , March 23, 2017 As ... years along with the prevalence of allergic diseases, ... measures are currently revolutionising the ways in which ... Allergies 2017 promises to be both a ... amongst the allergy interest groups, immunologists, research scholars ...
Breaking Medicine Technology: